Artificial Intelligence-driven Drug Design

Overview

AI-driven Drug Design (AIDD) is not a linear sequence handed off to separate vendors — it operates as an iterative loop. Quintara’s AI-driven antibody engineering platform delivers end-to-end capabilities: AI-guided discovery & design, molecular engineering (humanization, affinity maturation), high-throughput protein expression (1,000+ constructs per week), functional validation in disease-relevant cell models, ADCC/CDC and reporter assays, and early PK & safety profiling.

Consolidated onto one integrated platform, data from each step feeds downstream work and informs the next round of molecular design.

AI Loop

AI design and high-throughput wet lab in a closed-loop to deliver superior antibody leads

Seed Sequences
AI Opti™ Platform
Lead Candidates

Dry Lab

1. In-silico Design

Iterative design with input from previous rounds

Performance & Risk Scoring System

Train

Update AI model

with new data

4. Multi-Objective Optimization

Humanization & Affinity maturation

Sequence & Developability improvement

Immunogenicity prediction

Design

AI generates optimized antibody candidates

DBLT Closed-Loop

The AI model evolves iteratively with experimental data, improving prediction accuracy and better fitting project-specific needs.

Learn

Extract insights from experimental results

Wet Lab

2. HT Antibody Expression Platform

>1,000 / week from gene synthesis to antibody

Mammalian & Cell-free expression system

Build

Generate & express

candidate variants

3. HT Antibody Characterization

Developability assays

Functional assays

AI-driven Antibody Discovery Platform

Antibody Discovery

AI-driven predictive modeling accelerating the identification of novel antibody candidates with high efficiency.

Antibody Engineering

Molecular developability, stability, affinity, and manufacturability for clinical readiness.

HT Protein Expression

High-quality, scalable production using advanced expression systems and purification technologies.

Functional Validation

Deliver robust preclinical evidence through rigorous assays, providing solid POC for successful clinical translation.

Antibody Discovery

Phage Library

• Clinically validated framework

• Fully Human Synthetic, 10¹²-Scale
Yeast Library

• Multi-Parameter Directed Evolution

• Correct glycosylation and native folding
Single B Cell Technology

• Rapid immunization

• AI-driven virtual screening

AI-Assisted Sequence Design

Machine learning models driving rational antibody engineering

Optimally humanized
Enhanced Affinity
Superior Developability

Antibody Engineering

Humanization

• 3D structural & linear sequence analysis

• Key residue identification & germline gene selection

• CDR grafting & back-mutation

• Expression validation & affinity/Tm ranking
Affinity Maturation

• Display library construction & panning

• High-throughput variant screening & design

• Lead candidate ranking via functional assays

• Comprehensive affinity and stability characterization
Sequence Optimization

• AI-driven 3D structural modeling & scoring

• Identification & elimination of risk motifs

• In-silico variant developability design

• Enhanced expression yield & product quality
Developability Engineering

• Stability: Thermal stress & pH challenge accelerated assays

• Purity: Aggregate, fragment, and charge variant profiling

• Quantification: High-precision antibody titer measurement

• Risk: Early-stage developability assessment & mitigation
Customized Optimization

• BsAb: Fc heterodimerization & mispairing reduction engineering

• Prodrugs: Smart linker screening & masking peptide design

• AND-Logic: Bispecific antibodies with disease-specific selectivity

• Novel Formats: Tailored solutions for next-gen therapeutics

High-throughput Expression

Protein Expression Platform

Antibody / Antigen Expression & Production

High-throughput (1,000+) & scalable system for high-purity protein production.
High-throughput Affinity Detection (BLI & SPR)

Label-free, real-time analysis to precisely characterize binding kinetics and affinity constants.
Epitope Binning, Mapping, and Analysis

Detailed identification of antigenic determinants to elucidate binding specificity and MOA.

Developability and Functional Validation

Developability Assessment
- Sequence Assessment
  
  In silico analysis for germline homology, PTM liabilities, immunogenicity risk, and sequence similarity.
- Accelerated Stability
  
  4-week stability testing at high concentration to monitor drug integrity, concentration retention, and purity.
- Physicochemical Characterization
  
  Comprehensive profiling via SEC (aggregation), Tm (thermal stability), and self-association analysis.
- Whole Blood Stability
  
  Evaluates drug concentration and functional activity retention in a physiologically relevant whole blood matrix.
In Vitro Screening Strategy
- Binding Assays
  
  ELISA/FACS binding validation for target interaction.
- Competition Assays
  
  ELISA/FACS competition validation for binding specificity and assess epitope blocking potential.
- Target Overexpression Reporter Assay
  
  antibody-mediated target engagement confirmation using engineered reporter cell lines.
- Signaling Pathway Analysis
  
  Verification of key disease pathways in primary/pathological cells.
- Affinity Measurement
  
  Precision BLI/SPR affinity determination.